Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 130 entries
Sorted by: Best Match Show Resources per page
Clinical utility of treprostinil and its overall place in the treatment of pulmonary arterial hypertension.

Clinical medicine insights. Circulatory, respiratory and pulmonary medicine

Mirza S, Foley RJ.
PMID: 22872790
Clin Med Insights Circ Respir Pulm Med. 2012;6:41-50. doi: 10.4137/CCRPM.S8678. Epub 2012 Jul 24.

Pulmonary arterial hypertension (PAH) is a disease that leads to characteristic vascular wall remodeling and hemodynamic alterations. Consequently, this pulmonary vascular disease contributes to substantial morbidity and mortality in afflicted patients. PAH may be idiopathic in nature or associated...

Cite
Mirza S, Foley RJ. Clinical utility of treprostinil and its overall place in the treatment of pulmonary arterial hypertension. Clin Med Insights Circ Respir Pulm Med. 2012;6:41-50doi: 10.4137/CCRPM.S8678.
Mirza, S., & Foley, R. J. (2012). Clinical utility of treprostinil and its overall place in the treatment of pulmonary arterial hypertension. Clinical medicine insights. Circulatory, respiratory and pulmonary medicine, 641-50. https://doi.org/10.4137/CCRPM.S8678
Mirza, Shireen, and Foley, Raymond J. "Clinical utility of treprostinil and its overall place in the treatment of pulmonary arterial hypertension." Clinical medicine insights. Circulatory, respiratory and pulmonary medicine vol. 6 (2012): 41-50. doi: https://doi.org/10.4137/CCRPM.S8678
Mirza S, Foley RJ. Clinical utility of treprostinil and its overall place in the treatment of pulmonary arterial hypertension. Clin Med Insights Circ Respir Pulm Med. 2012;6:41-50. doi: 10.4137/CCRPM.S8678. Epub 2012 Jul 24. PMID: 22872790; PMCID: PMC3412595.
Copy Download .nbib Format: NLM
Fatal pulmonary arterial hypertension in an infant girl with incontinentia pigmenti.

Pediatrics international : official journal of the Japan Pediatric Society

Yasuda K, Minami N, Yoshikawa Y, Taketani T, Fukuda S, Yamaguchi S.
PMID: 27173419
Pediatr Int. 2016 May;58(5):394-396. doi: 10.1111/ped.12831.

We report the case of an infant girl with incontinentia pigmenti (IP) complicated by fatal pulmonary arterial hypertension (PAH). She was diagnosed with IP, based on the presence of specific skin lesions, neonatal seizures, hypereosinophilia and a maternal family...

Cite
Yasuda K, Minami N, Yoshikawa Y, et al. Fatal pulmonary arterial hypertension in an infant girl with incontinentia pigmenti. Pediatr Int. 2016;58(5):394-396doi: 10.1111/ped.12831.
Yasuda, K., Minami, N., Yoshikawa, Y., Taketani, T., Fukuda, S., & Yamaguchi, S. (2016). Fatal pulmonary arterial hypertension in an infant girl with incontinentia pigmenti. Pediatrics international : official journal of the Japan Pediatric Society, 58(5), 394-396. https://doi.org/10.1111/ped.12831
Yasuda, Kenji, et al. "Fatal pulmonary arterial hypertension in an infant girl with incontinentia pigmenti." Pediatrics international : official journal of the Japan Pediatric Society vol. 58,5 (2016): 394-396. doi: https://doi.org/10.1111/ped.12831
Yasuda K, Minami N, Yoshikawa Y, Taketani T, Fukuda S, Yamaguchi S. Fatal pulmonary arterial hypertension in an infant girl with incontinentia pigmenti. Pediatr Int. 2016 May;58(5):394-396. doi: 10.1111/ped.12831. PMID: 27173419.
Copy Download .nbib Format: NLM
Reported sildenafil side effects in pediatric pulmonary hypertension patients.

Frontiers in pediatrics

Siehr SL, McCarthy EK, Ogawa MT, Feinstein JA.
PMID: 25806361
Front Pediatr. 2015 Mar 09;3:12. doi: 10.3389/fped.2015.00012. eCollection 2015.

BACKGROUND: Sildenafil, a phosphodiestase type 5 inhibitor, was approved in 2005 for the treatment of pulmonary arterial hypertension (PAH) in adults and is commonly used off-label for pediatric patients. Little is known, however, about sildenafil's side effects in this...

Cite
Siehr SL, McCarthy EK, Ogawa MT, et al. Reported sildenafil side effects in pediatric pulmonary hypertension patients. Front Pediatr. 2015;3:12doi: 10.3389/fped.2015.00012.
Siehr, S. L., McCarthy, E. K., Ogawa, M. T., & Feinstein, J. A. (2015). Reported sildenafil side effects in pediatric pulmonary hypertension patients. Frontiers in pediatrics, 312. https://doi.org/10.3389/fped.2015.00012
Siehr, Stephanie L, et al. "Reported sildenafil side effects in pediatric pulmonary hypertension patients." Frontiers in pediatrics vol. 3 (2015): 12. doi: https://doi.org/10.3389/fped.2015.00012
Siehr SL, McCarthy EK, Ogawa MT, Feinstein JA. Reported sildenafil side effects in pediatric pulmonary hypertension patients. Front Pediatr. 2015 Mar 09;3:12. doi: 10.3389/fped.2015.00012. eCollection 2015. PMID: 25806361; PMCID: PMC4353247.
Copy Download .nbib Format: NLM
Critical illness associated with 2013-2014 influenza A (H1N1): Postpandemic characteristics, presentation and outcomes.

Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine

Wiesen J, Joshi D, Guzman JA, Duggal A.
PMID: 26730113
Indian J Crit Care Med. 2015 Nov;19(11):636-41. doi: 10.4103/0972-5229.169328.

INTRODUCTION: The United States experienced a postpandemic outbreak of H1N1 influenza in 2013-2014. Unlike the pandemic in 2009 clinical course and outcomes associated with critical illness in this postpandemic outbreak has been only sparsely described.METHODS: We conducted a retrospective...

Cite
Wiesen J, Joshi D, Guzman JA, et al. Critical illness associated with 2013-2014 influenza A (H1N1): Postpandemic characteristics, presentation and outcomes. Indian J Crit Care Med. 2015;19(11):636-41doi: 10.4103/0972-5229.169328.
Wiesen, J., Joshi, D., Guzman, J. A., & Duggal, A. (2015). Critical illness associated with 2013-2014 influenza A (H1N1): Postpandemic characteristics, presentation and outcomes. Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine, 19(11), 636-41. https://doi.org/10.4103/0972-5229.169328
Wiesen, Jonathan, et al. "Critical illness associated with 2013-2014 influenza A (H1N1): Postpandemic characteristics, presentation and outcomes." Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine vol. 19,11 (2015): 636-41. doi: https://doi.org/10.4103/0972-5229.169328
Wiesen J, Joshi D, Guzman JA, Duggal A. Critical illness associated with 2013-2014 influenza A (H1N1): Postpandemic characteristics, presentation and outcomes. Indian J Crit Care Med. 2015 Nov;19(11):636-41. doi: 10.4103/0972-5229.169328. PMID: 26730113; PMCID: PMC4687171.
Copy Download .nbib Format: NLM
Comparison of inhaled milrinone, nitric oxide and prostacyclin in acute respiratory distress syndrome.

World journal of critical care medicine

Albert M, Corsilli D, Williamson DR, Brosseau M, Bellemare P, Delisle S, Nguyen AQ, Varin F.
PMID: 28224110
World J Crit Care Med. 2017 Feb 04;6(1):74-78. doi: 10.5492/wjccm.v6.i1.74. eCollection 2017 Feb 04.

AIM: To evaluate the safety and efficacy of inhaled milrinone in acute respiratory distress syndrome (ARDS).METHODS: Open-label prospective cross-over pilot study where fifteen adult patients with hypoxemic failure meeting standard ARDS criteria and monitored with a pulmonary artery catheter...

Cite
Albert M, Corsilli D, Williamson DR, et al. Comparison of inhaled milrinone, nitric oxide and prostacyclin in acute respiratory distress syndrome. World J Crit Care Med. 2017;6(1):74-78doi: 10.5492/wjccm.v6.i1.74.
Albert, M., Corsilli, D., Williamson, D. R., Brosseau, M., Bellemare, P., Delisle, S., Nguyen, A. Q., & Varin, F. (2017). Comparison of inhaled milrinone, nitric oxide and prostacyclin in acute respiratory distress syndrome. World journal of critical care medicine, 6(1), 74-78. https://doi.org/10.5492/wjccm.v6.i1.74
Albert, Martin, et al. "Comparison of inhaled milrinone, nitric oxide and prostacyclin in acute respiratory distress syndrome." World journal of critical care medicine vol. 6,1 (2017): 74-78. doi: https://doi.org/10.5492/wjccm.v6.i1.74
Albert M, Corsilli D, Williamson DR, Brosseau M, Bellemare P, Delisle S, Nguyen AQ, Varin F. Comparison of inhaled milrinone, nitric oxide and prostacyclin in acute respiratory distress syndrome. World J Crit Care Med. 2017 Feb 04;6(1):74-78. doi: 10.5492/wjccm.v6.i1.74. eCollection 2017 Feb 04. PMID: 28224110; PMCID: PMC5295172.
Copy Download .nbib Format: NLM
Medication and patient factors associated with adherence to pulmonary hypertension targeted therapies.

Pulmonary circulation

Grady D, Weiss M, Hernandez-Sanchez J, Pepke-Zaba J.
PMID: 29099657
Pulm Circ. 2018 Jan-Mar;8(1):2045893217743616. doi: 10.1177/2045893217743616. Epub 2017 Nov 03.

The aims of this study were to investigate the medication adherence of patients on pulmonary hypertension (PH)-targeted therapies and uncover factors that might influence adherence values. Patients taking at least one specialist medicine (sildenafil, tadalafil, bosentan, ambrisentan, iloprost, epoprostenol,...

Cite
Grady D, Weiss M, Hernandez-Sanchez J, et al. Medication and patient factors associated with adherence to pulmonary hypertension targeted therapies. Pulm Circ. 2017;8(1):2045893217743616doi: 10.1177/2045893217743616.
Grady, D., Weiss, M., Hernandez-Sanchez, J., & Pepke-Zaba, J. (2018). Medication and patient factors associated with adherence to pulmonary hypertension targeted therapies. Pulmonary circulation, 8(1), 2045893217743616. https://doi.org/10.1177/2045893217743616
Grady, Duncan, et al. "Medication and patient factors associated with adherence to pulmonary hypertension targeted therapies." Pulmonary circulation vol. 8,1 (2018): 2045893217743616. doi: https://doi.org/10.1177/2045893217743616
Grady D, Weiss M, Hernandez-Sanchez J, Pepke-Zaba J. Medication and patient factors associated with adherence to pulmonary hypertension targeted therapies. Pulm Circ. 2018 Jan-Mar;8(1):2045893217743616. doi: 10.1177/2045893217743616. Epub 2017 Nov 03. PMID: 29099657; PMCID: PMC5731720.
Copy Download .nbib Format: NLM
Cyclophosphamide for scleroderma interstitial lung disease. Tashkin DP, Elashoff R, Clements PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. (2006) 354(25):2655-2666.

Expert opinion on investigational drugs

Antoniu SA.
PMID: 17302533
Expert Opin Investig Drugs. 2007 Mar;16(3):393-5. doi: 10.1517/13543784.16.3.393.

Systemic sclerosis (scleroderma) is a chronic debilitating disease that is caused by the occurrence of fibrotic changes and vascular abnormalities at various levels such as: skin, lungs, kidneys or heart. Lung involvement in scleroderma is represented by scleroderma interstitial...

Cite
Antoniu SA. Cyclophosphamide for scleroderma interstitial lung disease. Tashkin DP, Elashoff R, Clements PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. (2006) 354(25):2655-2666. Expert Opin Investig Drugs. 2007;16(3):393-5doi: 10.1517/13543784.16.3.393.
Antoniu, S. A. (2007). Cyclophosphamide for scleroderma interstitial lung disease. Tashkin DP, Elashoff R, Clements PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. (2006) 354(25):2655-2666. Expert opinion on investigational drugs, 16(3), 393-5. https://doi.org/10.1517/13543784.16.3.393
Antoniu, Sabina A. "Cyclophosphamide for scleroderma interstitial lung disease. Tashkin DP, Elashoff R, Clements PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. (2006) 354(25):2655-2666." Expert opinion on investigational drugs vol. 16,3 (2007): 393-5. doi: https://doi.org/10.1517/13543784.16.3.393
Antoniu SA. Cyclophosphamide for scleroderma interstitial lung disease. Tashkin DP, Elashoff R, Clements PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. (2006) 354(25):2655-2666. Expert Opin Investig Drugs. 2007 Mar;16(3):393-5. doi: 10.1517/13543784.16.3.393. PMID: 17302533.
Copy Download .nbib Format: NLM
Continuous intravenous epoprostenol improved survival, clinical status and hemodynamics in patients with severe primary pulmonary hypertension.

Evidence-based cardiovascular medicine

Terrin ML.
PMID: 16379691
Evid Based Cardiovasc Med. 1997 Apr;1(1):21. doi: 10.1016/s1361-2611(97)80090-5.

No abstract available.

Cite
Terrin ML. Continuous intravenous epoprostenol improved survival, clinical status and hemodynamics in patients with severe primary pulmonary hypertension. Evid Based Cardiovasc Med. 1997;1(1):21doi: 10.1016/s1361-2611(97)80090-5.
Terrin, M. L. (1997). Continuous intravenous epoprostenol improved survival, clinical status and hemodynamics in patients with severe primary pulmonary hypertension. Evidence-based cardiovascular medicine, 1(1), 21. https://doi.org/10.1016/s1361-2611(97)80090-5
Terrin, M L. "Continuous intravenous epoprostenol improved survival, clinical status and hemodynamics in patients with severe primary pulmonary hypertension." Evidence-based cardiovascular medicine vol. 1,1 (1997): 21. doi: https://doi.org/10.1016/s1361-2611(97)80090-5
Terrin ML. Continuous intravenous epoprostenol improved survival, clinical status and hemodynamics in patients with severe primary pulmonary hypertension. Evid Based Cardiovasc Med. 1997 Apr;1(1):21. doi: 10.1016/s1361-2611(97)80090-5. PMID: 16379691.
Copy Download .nbib Format: NLM
Interim prostacyclin therapy for an isolated disconnected pulmonary artery: a case report.

Journal of medical case reports

Grech V, Grixti C.
PMID: 20525186
J Med Case Rep. 2010 Jun 02;4:168. doi: 10.1186/1752-1947-4-168.

INTRODUCTION: Disconnected pulmonary arteries are unusual and may result in pulmonary hypertension with acute right heart failure.CASE PRESENTATION: We report a case of a three-month-old Asian girl who presented with heart failure and severe pulmonary hypertension due to a...

Cite
Grech V, Grixti C. Interim prostacyclin therapy for an isolated disconnected pulmonary artery: a case report. J Med Case Rep. 2010;4:168doi: 10.1186/1752-1947-4-168.
Grech, V., & Grixti, C. (2010). Interim prostacyclin therapy for an isolated disconnected pulmonary artery: a case report. Journal of medical case reports, 4168. https://doi.org/10.1186/1752-1947-4-168
Grech, Victor, and Grixti, Cynthia. "Interim prostacyclin therapy for an isolated disconnected pulmonary artery: a case report." Journal of medical case reports vol. 4 (2010): 168. doi: https://doi.org/10.1186/1752-1947-4-168
Grech V, Grixti C. Interim prostacyclin therapy for an isolated disconnected pulmonary artery: a case report. J Med Case Rep. 2010 Jun 02;4:168. doi: 10.1186/1752-1947-4-168. PMID: 20525186; PMCID: PMC2894860.
Copy Download .nbib Format: NLM
Pulmonary hypertension.

Drugs of today (Barcelona, Spain : 1998)

Moraes D, Loscalzo J.
PMID: 14743257
Drugs Today (Barc). 1998 Oct;34(10):855-64. doi: 10.1358/dot.1998.34.10.487472.

Pulmonary hypertension can be caused by an increase in pulmonary blood flow, an increase in left-heart impedance or an increase in pulmonary vascular resistance. Although there are many specific causes that have been identified, clinical presentation and natural history...

Cite
Moraes D, Loscalzo J. Pulmonary hypertension. Drugs Today (Barc). 1998;34(10):855-64doi: 10.1358/dot.1998.34.10.487472.
Moraes, D., & Loscalzo, J. (1998). Pulmonary hypertension. Drugs of today (Barcelona, Spain : 1998), 34(10), 855-64. https://doi.org/10.1358/dot.1998.34.10.487472
Moraes, D, and Loscalzo, J. "Pulmonary hypertension." Drugs of today (Barcelona, Spain : 1998) vol. 34,10 (1998): 855-64. doi: https://doi.org/10.1358/dot.1998.34.10.487472
Moraes D, Loscalzo J. Pulmonary hypertension. Drugs Today (Barc). 1998 Oct;34(10):855-64. doi: 10.1358/dot.1998.34.10.487472. PMID: 14743257.
Copy Download .nbib Format: NLM
Intravenous Epoprostenol for Management of Pulmonary Arterial Hypertension during Pregnancy.

AJP reports

Timofeev J, Ruiz G, Fries M, Driggers RW.
PMID: 24147238
AJP Rep. 2013 Oct;3(2):71-4. doi: 10.1055/s-0033-1338169. Epub 2013 Mar 18.

Background Pulmonary arterial hypertension carries a high risk of mortality in pregnancy. Recent advances in treatment may improve disease course and allow for successful management of the pregnancy. Case Report We present the case of a 20-year-old gravida 1,...

Cite
Timofeev J, Ruiz G, Fries M, et al. Intravenous Epoprostenol for Management of Pulmonary Arterial Hypertension during Pregnancy. AJP Rep. 2013;3(2):71-4doi: 10.1055/s-0033-1338169.
Timofeev, J., Ruiz, G., Fries, M., & Driggers, R. W. (2013). Intravenous Epoprostenol for Management of Pulmonary Arterial Hypertension during Pregnancy. AJP reports, 3(2), 71-4. https://doi.org/10.1055/s-0033-1338169
Timofeev, Julia, et al. "Intravenous Epoprostenol for Management of Pulmonary Arterial Hypertension during Pregnancy." AJP reports vol. 3,2 (2013): 71-4. doi: https://doi.org/10.1055/s-0033-1338169
Timofeev J, Ruiz G, Fries M, Driggers RW. Intravenous Epoprostenol for Management of Pulmonary Arterial Hypertension during Pregnancy. AJP Rep. 2013 Oct;3(2):71-4. doi: 10.1055/s-0033-1338169. Epub 2013 Mar 18. PMID: 24147238; PMCID: PMC3799704.
Copy Download .nbib Format: NLM
The Clinical Impact of Flow Titration on Epoprostenol Delivery via High Flow Nasal Cannula for ICU Patients with Pulmonary Hypertension or Right Ventricular Dysfunction: A Retrospective Cohort Comparison Study.

Journal of clinical medicine

Li J, Gurnani PK, Roberts KM, Fink JB, Vines D.
PMID: 32046152
J Clin Med. 2020 Feb 07;9(2). doi: 10.3390/jcm9020464.

(1) Background: inhaled epoprostenol (iEPO) delivered via high-flow nasal cannula (HFNC) has been reported to be effective for pulmonary hypertension and right ventricular dysfunction. In vitro studies have identified HFNC gas flow as a key factor in trans-nasal aerosol...

Cite
Li J, Gurnani PK, Roberts KM, et al. The Clinical Impact of Flow Titration on Epoprostenol Delivery via High Flow Nasal Cannula for ICU Patients with Pulmonary Hypertension or Right Ventricular Dysfunction: A Retrospective Cohort Comparison Study. J Clin Med. 2020;9(2)doi: 10.3390/jcm9020464.
Li, J., Gurnani, P. K., Roberts, K. M., Fink, J. B., & Vines, D. (2020). The Clinical Impact of Flow Titration on Epoprostenol Delivery via High Flow Nasal Cannula for ICU Patients with Pulmonary Hypertension or Right Ventricular Dysfunction: A Retrospective Cohort Comparison Study. Journal of clinical medicine, 9(2), . https://doi.org/10.3390/jcm9020464
Li, Jie, et al. "The Clinical Impact of Flow Titration on Epoprostenol Delivery via High Flow Nasal Cannula for ICU Patients with Pulmonary Hypertension or Right Ventricular Dysfunction: A Retrospective Cohort Comparison Study." Journal of clinical medicine vol. 9,2 (2020). doi: https://doi.org/10.3390/jcm9020464
Li J, Gurnani PK, Roberts KM, Fink JB, Vines D. The Clinical Impact of Flow Titration on Epoprostenol Delivery via High Flow Nasal Cannula for ICU Patients with Pulmonary Hypertension or Right Ventricular Dysfunction: A Retrospective Cohort Comparison Study. J Clin Med. 2020 Feb 07;9(2). doi: 10.3390/jcm9020464. PMID: 32046152; PMCID: PMC7074129.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 130 entries